POMDOCTOR Deepens AI-Driven Chronic Disease Strategy as Predictive Healthcare Demand Surges
TipRanks (Thu, 9-Jul 8:47 AM ET)
PRNewswire (Thu, 9-Jul 8:00 AM ET)
PRNewswire (Thu, 2-Jul 8:00 AM ET)
POMDOCTOR LIMITED Announces ADS Ratio Change to Be Effective on June 22, 2026
PRNewswire (Wed, 17-Jun 6:00 AM ET)
POMDOCTOR LIMITED Announces Plan to Implement ADS Ratio Change
PRNewswire (Thu, 28-May 8:00 AM ET)
POMDOCTOR LIMITED Announces Fiscal Year 2025 Financial Results
PRNewswire (Thu, 14-May 4:30 PM ET)
Newsfile (Mon, 13-Apr 4:17 PM ET)
Business Wire (Mon, 13-Apr 12:37 PM ET)
PRNewswire (Sun, 12-Apr 11:41 AM ET)
Pomdoctor Ltd is an online medical services platform for chronic diseases in China. With a focus on chronic disease management and pharmaceutical services, its business model forms a one-stop platform for medical services, which organically connects patients to doctors and pharmaceutical products. Its experience in tackling chronic diseases can be traced back to the launch of its platform on mobile devices. The company operates in two segments: Internet hospital, and Pharmaceutical supply chain. The majority of its revenue is derived from the Pharmaceutical supply chain segment.
Pomdoctor Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol POM.
As of July 10, 2026, POM stock price declined to $1.53 with 29,526 million shares trading.
POM has a beta of 0.39, meaning it tends to be less sensitive to market movements. POM has a correlation of 0.00 to the broad based SPY ETF.
POM has a market cap of $182.37 million. This is considered a Micro Cap stock.
POM support price is $1.46 and resistance is $1.84 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that POM shares will trade within this expected range on the day.